Datapoint: Court Ruling Shores Up Eliquis Exclusivity Until 2028

The U.S. Court of Appeals for the Federal Circuit on Sept. 3 upheld a lower court decision that maintains Bristol Myers Squibb and Pfizer’s U.S. exclusivity for their blockbuster heart drug Eliquis until 2028. The ruling is still subject to appeal, however. Eliquis is one of the top-selling drugs in the U.S., and currently holds covered or better status for 98% of all insured lives under the pharmacy benefit. 82.3% of all covered lives have unrestricted preferred access to Eliquis.

SOURCE: MMIT Analytics, as of 9/8/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today